Form D · Biotechnology
VERAX BIOMEDICAL INC
Marlborough, MA · CIK 0001161304
Offering snapshot reported Sep 19, 2019 · SEC filing
- Reported sold
- $2.54M Offering amount: $10.5M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 5, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 19, 2019 | Initial | $2,538,912 | No comparison | 5 | SEC filing |
| Nov 13, 2017 | Initial | $11,439,595 | No comparison | 4 | SEC filing |
| Jun 27, 2016 | Amendment | $12,614,469 | $60,104vs Mar 2, 2016 | 64 | SEC filing |
| Mar 2, 2016 | Initial | $12,554,365 | No comparison | 56 | SEC filing |
| Jan 21, 2015 | Initial | $4,000,000 | No comparison | 61 | SEC filing |
| Oct 15, 2013 | Amendment | $8,499,302 | $1,667,310vs Jul 31, 2013 | 83 | SEC filing |
| Jul 31, 2013 | Initial | $6,831,992 | No comparison | 31 | SEC filing |
| Oct 25, 2012 | Amendment | $3,298,121 | $509,808vs Aug 14, 2012 | 86 | SEC filing |
| Aug 14, 2012 | Initial | $2,788,313 | No comparison | 11 | SEC filing |
| Mar 22, 2011 | Initial | $1,287,036 | No comparison | 26 | SEC filing |
| Apr 15, 2009 | Initial | $2,079,142 | No comparison | Not reported | SEC filing |
| Sep 26, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 11, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Aug 16, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $425K
- Finders' fees
- $0
- Form D file number
- 021-349251
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Four Points Capital Partners LLC | 43149 | Thomas Frederick Zipser · CRD 5248930 |
Source: Form D, filed Sep 19, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Buzz Benson | Director |
| Joe Del Guercio | Director |
| Robert Flanagan | Director |
| Marc Goldberg | Director |
| Jeffrey A. Hall | Executive |
| Nancy A. Hornbaker | Executive |
| James Koziarz | Director |
| Gregory Lawrence | Executive |
| Greg Lawrence | Executive |
| James Lousararian | Director, Executive |
| R. Scott Mckenzie | Executive |
| R. Scott Mckenzie, Sr. | Executive |
| Paul Ragusa | Executive |
| Joe Sanders | Director |
| Yli Remo Vallejo | Executive |
| Robert Zieserl | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Verax Biomedical Incorporated 148 Bartlett Street
Marlborough, MA, 01752
Marlborough, MA, 01752